Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep;63(3):313-323.
doi: 10.1016/j.amepre.2022.02.019. Epub 2022 Jul 21.

Antihypertensive and Statin Medication Adherence Among Medicare Beneficiaries

Sandra L Jackson  1 , Priya R Nair  2 , Anping Chang  2 , Linda Schieb  2 , Fleetwood Loustalot  2 , Hilary K Wall  2 , Laurence S Sperling  2 , Matthew D Ritchey  3
Affiliations

Antihypertensive and Statin Medication Adherence Among Medicare Beneficiaries

Sandra L Jackson et al. Am J Prev Med. 2022 Sep.

Abstract

Introduction: Medication adherence is important for optimal management of chronic conditions, including hypertension and hypercholesterolemia. This study describes adherence to antihypertensive and statin medications, individually and collectively, and examines variation in adherence by demographic and geographic characteristics.

Methods: The 2017 prescription drug event data for beneficiaries with Medicare Part D coverage were assessed. Beneficiaries with a proportion of days covered ≥80% were considered adherent. Adjusted prevalence ratios were estimated to quantify the associations between demographic and geographic characteristics and adherence. Adherence estimates were mapped by county of residence using a spatial empirical Bayesian smoothing technique to enhance stability. Analyses were conducted in 2019‒2021.

Results: Among the 22.5 million beneficiaries prescribed antihypertensive medications, 77.1% were adherent; among the 16.1 million prescribed statin medications, 81.9% were adherent; and among the 13.5 million prescribed antihypertensive and statin medications, 70.3% were adherent to both. Adherence varied by race/ethnicity: American Indian/Alaska Native (adjusted prevalence ratio=0.83, 95% confidence limit=0.82, 0.842), Hispanic (adjusted prevalence ratio=0.90, 95% confidence limit=0.90, 0.91), and non-Hispanic Black (adjusted prevalence ratio=0.87, 95% confidence limit=0.86, 0.87) beneficiaries were less likely to be adherent than non-Hispanic White beneficiaries. County-level adherence ranged across the U.S. from 25.7% to 88.5% for antihypertensive medications, from 36.0% to 93.8% for statin medications, and from 20.8% to 92.9% for both medications combined and tended to be the lowest in the southern U.S.

Conclusions: This study highlights opportunities for efforts to remove barriers and support medication adherence, especially among racial/ethnic minority groups and within the regions at greatest risk for adverse cardiovascular outcomes.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to disclose.

Figures

FIGURE 1.
FIGURE 1.
Adjusted a prevalence ratio for adherence to antihypertensive and statin medications, by county urbanicity and race/ethnicity, Medicare Part D, 2017 Abbreviations: API= Asian/Pacific Islander; AI/AN= American Indian/Alaska Native; NH = Non-Hispanic a Fully adjusted, where appropriate, by age, sex, income status, medication plan type, urban/rural classification, fixed-dose use (any), mail order user (any), and continuity of care. The referent group is non-Hispanic White beneficiaries.
FIGURE 2:
FIGURE 2:
Prevalence of antihypertensive and statin medication adherence among Medicare Part D beneficiaries aged ≥65 years, by county — United States, Puerto Rico, and U.S. Virgin Islands, 2017
See this image and copyright information in PMC

References

    1. Ritchey MD, Wall HK, George MG, Wright JS. US trends in premature heart disease mortality over the past 50 years: Where do we go from here? Trends Cardiovasc Med 2020;30(6):364–374. - PMC - PubMed
    1. Virani SS, Alonso A, Aparicio HJ, Benjamin EJ, Bittencourt MS, Callaway CW, et al. Heart Disease and Stroke Statistics-2021 Update: A Report From the American Heart Association. Circulation 2021;143(8):e254–e743. - PubMed
    1. Zhang D, Wang G, Zhang P, Fang J, Ayala C. Medical Expenditures Associated With Hypertension in the U.S., 2000–2013. Am J Prev Med 2017;53(6S2):S164–S171. - PMC - PubMed
    1. Whelton PK, Carey RM, Aronow WS, Casey DE Jr., Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension 2018;71(6):1269–1324. - PubMed
    1. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019;139(25):e1082–e1143. - PMC - PubMed

Substances